Kairos PharmaKAPA +7.49%15 Market Cap is $8.22 Mil as of Jun. 30, 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 1,428 Biotechnology companies, Kairos Pharma ranks worse than 86.97% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kairos Pharma's share price for the quarter that ended in Mar. 2026 was $0.559. Kairos Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 21.41 Mil. Therefore, Kairos Pharma's market cap for the quarter that ended in Mar. 2026 was $11.97 Mil.
Kairos Pharma's quarterly market cap
declined
from Sep. 2025 ($24.36 Mil) to Dec. 2025 ($14.78 Mil) and
declined
from Dec. 2025 ($14.78 Mil) to Mar. 2026 ($11.97 Mil).
Kairos Pharma's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($20.88 Mil) but then
declined
from Dec. 2024 ($20.88 Mil) to Dec. 2025 ($14.78 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kairos Pharma's Enterprise Value for Today is $5.14 Mil.
Kairos Pharma (AMEX:KAPA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kairos Pharma Market Cap Related Terms
Kairos Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Kairos Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kairos Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kairos Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kairos Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Kairos Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kairos Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kairos Pharma (KAPA) has a Market Cap of $8.22 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #1242 out of 1428 companies in the Biotechnology industry, placing it in the top 87%.
Is Kairos Pharma's Market Cap too high?
Kairos Pharma's current Market Cap is $8.22 Mil. The Biotechnology industry median Market Cap is 119.44. Kairos Pharma's value of $8.22 Mil is 93.1% below this industry median. Based on the distribution chart, Kairos Pharma ranks #1242 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Market Cap compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #1242 out of 1428 companies for Market Cap. This places Kairos Pharma in the lower half of its industry. The industry median Market Cap is 119.44. Kairos Pharma's value of $8.22 Mil is 93.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kairos Pharma's current Market Cap of $8.22 Mil is 93.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kairos Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kairos Pharma's current Market Cap is $8.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Market Cap of $8.22 Mil. The current Market Cap is $8.22 Mil and 93.1% below the Biotechnology industry median of 119.44. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Market Cap is $8.22 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score
Get the complete analysis for KAPA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAPA has been successfully added to your 
